yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Top Links You Must Click On

Astro-Med, Inc. Reports Fourth Quarter and Fiscal 2009 Results; Directors Declare Quarterly Cash Dividend

WEST WARWICK, RI -- (Marketwire) -- 03/17/09 -- Astro-Med, Inc. (NASDAQ: ALOT) reports net income of $263,000, equal to $0.04 per diluted share on sales of $15,631,000 for the Fourth Quarter ended January 31, 2009. During the comparable period of the previous year, the Company reported net income of $1,340,000, equal to $0.18 per diluted share on sales of $18,131,000.

Net income in the prior year's Fourth Quarter included a restructuring charge of approximately $316,000 after tax equal to $0.04 per diluted share. The previous year's Fourth Quarter net income also included a tax benefit of $739,000, equal to $0.10 per diluted share related to the closing of our sales and service offices in Italy and the Netherlands.

During the twelve-month period of the fiscal year, net income was $2,964,000, equal to $0.40 per diluted share on sales of $71,783,000. For the comparable period last year, the Company reported net income of $4,310,000, equal to $0.57 per diluted share on sales of $72,371,000.

In addition to the restructuring charge, net income in the prior fiscal year includes tax benefits of $1,185,000 or $0.15 per diluted share due to favorable reduction of certain income tax examinations as well as benefits related to the disposition of the Company's subsidiary in Italy, noted above.

Commenting on the results, Albert W. Ondis, Chief Executive Officer, said, "For the year which ended January 31, 2009, the Company achieved sales of $71,783,000, improved Gross Profit Margins to 43.3%, raised the operating income margin to 6.4% and earned net income of approximately $3,000,000 or $.40 per diluted share. In addition, the Company added $4,500,000 to its cash and marketable securities balance of $22,105,000 to maintain a current ratio of 6.08:1. During the year we introduced four new major products, strengthened our field sales organization and formalized our acquisition strategy. Astro-Med's focus and energy will continue to center on achieving our Mission of customer-centered sales growth, increased profitability, and enhanced shareholder value.

"As we stated in our preliminary earnings and sales statement of February 18, 2009, the effects of the economic slowdown were rather broadly felt, particularly in our QuickLabel Systems product lines. QuickLabel Systems products, which serve the packaging industry, are closest to retail markets so that QuickLabel product demand fluctuates with consumer demand. As retail consumers cut back on purchases in all geographic markets, sales of our label printing consumables and label printers slowed significantly. The sales decline was felt most in the United States, but our export sales were also affected.

"We also felt a rather sudden slow down in sales of our Test & Measurement product lines since these data recorder and telemetry products are considered capital equipment purchases, and many businesses and organizations applied the brakes quite summarily to such purchases. Sales of our Ruggedized Products line, consisting principally of the special cockpit printers we make for aircraft such as the new Boeing 787, the Airbus A380, and certain models of the Boeing 747 and Boeing 777, were negatively impacted by the well-publicized production delays at both Boeing and Airbus. Demand was also impacted by the slow down in passenger air travel which has led the airlines to postpone new airplane deliveries."

However, in the face of these negative developments, Ondis concluded, "Our Grass Technologies product lines achieved strong sales as our sleep diagnostic and other neurological diagnostic and research products gathered increased acceptance from customers around the world."

Cost-Reduction Initiative

Ondis described a program of cost-reduction now underway at Astro-Med. "Notwithstanding the favorable news from our Grass Technologies product line, we have already instituted an austerity program to mitigate the effects of the business slowdown. Included and already in effect are wage and salary freezes, layoffs, and a general reduction in the working hours of most of our employees involved in production. We are continuing all R&D activities as we believe that the development of advanced new products will promote the growth and profitability of Astro-Med," said Ondis.

Directors Declare Quarterly Dividend

On March 5, 2009, the Directors of Astro-Med declared the regular quarterly cash dividend of $0.06 per share, payable on April 3, 2009 to shareholders of record on March 20, 2009.

Conference Call Scheduled for March 18, 2009 at 11:00 am

The Fourth Quarter conference call will be held on Wednesday, March 18, 2009 at 11:00 AM EDT. It will be broadcast in real time on the Internet through the Investing section of our website. We invite you to log on and listen in real time on March 18th, or to participate in the conference call by dialing 800-240-2430. Following the live broadcast, an audio webcast of the call will be available for ten days at A conference call replay will also be available for ten days by dialing 800-405-2236.

About Astro-Med, Inc.

Astro-Med, Inc. is a leading manufacturer of specialty high tech printing systems, electronic medical instrumentation, and test and measurement instruments. Astro-Med, Inc. products are sold under the brand names Astro-Med®, Grass® Technologies and QuickLabel® Systems and are employed around the world in a wide range of aerospace, medical, military, industrial, and packaging applications. Astro-Med, Inc. is a member of the Russell Microcap® Index. Additional information is available by visiting

Safe Harbor Statement

This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include those mentioned in Astro-Med's FY2008 annual report and its quarterly filings with the Securities and Exchange Commission.

                             ASTRO-MED, INC.

                   Consolidated Statements of Operations
                  In Thousands Except for Per Share Data

                                 Three-Months Ended   Twelve-Months Ended
                                 January    January    January    January
                                31, 2009   31, 2008   31, 2009   31, 2008
                                ---------  ---------  ---------  ---------
Net Sales                       $  15,631  $  18,131  $  71,783  $  72,371

Gross Profit                        6,553      8,062  $  31,068  $  31,111
                                     41.9%      44.5%      43.3%      43.0%
Operating Expenses:
  Selling                           4,014      4,508     16,942     17,126
  Research & Development            1,205      1,172      4,885      4,589
  General & Administration          1,020      1,290      4,615      4,682
  Restructuring Charge                  -        515          -        515
                                ---------  ---------  ---------  ---------
                                    6,239      7,485     26,442     26,912

Operating Income                      314        577      4,626      4,199
                                      2.0%       3.2%       6.4%       5.8%

Other Income (Expense), Net           (49)       222        (49)       855
                                ---------  ---------  ---------  ---------

Income Before Taxes                   265        799      4,577      5,054

Income Tax (Provision)/Benefit         (2)       541      1,613       (744)
                                ---------  ---------  ---------  ---------

Net Income                      $     263  $   1,340  $   2,964  $   4,310
                                ---------  ---------  ---------  ---------

Net Income Per Share - Basic    $    0.04  $    0.19  $    0.42  $    0.63
                                ---------  ---------  ---------  ---------
Net Income Per Share - Diluted  $    0.04  $    0.18  $    0.40  $    0.57
                                ---------  ---------  ---------  ---------

Weighted Average Number of
 Common Shares - Basic              7,010      6,896      6,988      6,885
Weighted Average Number of
 Common Shares - Diluted            7,313      7,473      7,438      7,532

Dividends Declared Per Common
 Share                          $    0.06  $    0.05  $    0.24  $    0.20

                      Selected Balance Sheet Data
                        In Thousands (Unaudited)
                                                       As of       As of
                                                    January 31, January 31,
                                                        2009        2008
                                                    ----------- -----------

Cash & Marketable Securities*                       $    22,105 $    17,556

Current Assets                                      $    48,023 $    48,384

Total Assets                                        $    62,155 $    61,699

Current Liabilities                                 $     7,904 $     8,973

Shareholders’ Equity                                $    51,471 $    49,355

* Includes LT investments

Reconciliation of Non-GAAP Financial Information

In an effort to provide investors information regarding the Company's results, the Company disclosed certain Non-GAAP information which management believes provides useful information to the investor in order for them to understand the certain adjustments impacting the Company's results of operations.

A reconciliation of net income and net income per diluted share as reported under GAAP to the Non-GAAP net income and net income per diluted share for the three-months and twelve-months ended January 31, 2009 and January 31, 2008 is as follows in ($000's):

                                 Three-Months Ended   Twelve-Months Ended
                                --------------------  --------------------
                                1/31/2009  1/31/2008  1/31/2009  1/31/2008
                                ---------  ---------  ---------  ---------
Operating Income - GAAP         $     314  $     577  $   4,626  $   4,199
Restructuring Charge                    _        515          _        515
                                ---------  ---------  ---------  ---------
Operating Income                      314      1,092      4,626      4,714
Other Income, Net                     (49)       222        (49)       855
                                ---------  ---------  ---------  ---------
Income Before Tax                     265      1,314      4,577      5,569
Income Tax Benefit (1)                  _        707          _      1,153
Income Tax (Provision) (2)             (2)    (1,104)    (1,613)    (3,281)
                                ---------  ---------  ---------  ---------
Net Income - Non GAAP (3)       $     263  $     917  $   2,964  $   3,441
                                ---------  ---------  ---------  ---------
EPS Per Share-Basic - Non
 GAAP(3)                        $    0.04  $    0.13  $    0.42  $    0.50
EPS Per Share-Diluted
 - Non GAAP (3)                 $    0.04  $    0.12  $    0.40  $    0.46

(1) Represents tax adjustments associated with the following items:
     (a) During the Fourth Quarter of Fiscal 2008 tax benefit of $739 on
         the disposition on the Italian Subsidiary and tax expense of $32
         on certain FIN48 adjustments
     (b) During Fiscal 2008 tax benefit of $739 on the disposition of the
         Italian Subsidiary, tax expense of $32 on certain FIN48
         adjustments and a $446 tax benefit on the favorable resolution of
         certain income tax examinations recorded in the third quarter
(2) Represents the following items:
     (a) During the fourth quarter of Fiscal 2008 income tax expense of
         $365 and the exclusion of the tax benefit of $739 on the
         disposition of the Italian subsidiary
     (b) During Fiscal 2008 income tax expense of $2,096, the exclusion of
         the tax benefit of $739 on the disposition of the Italian
         Subsidiary and the exclusion of the $446 due to favorable
         resolution of certain income tax examinations
(3) Pertains to FY 2008 only.

Albert W. Ondis
Joseph P. O'Connell
Astro-Med, Inc.
(401) 828-4000

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Enterprise Open Source Magazine Latest Stories . . .
Meet one of the top essential oils that is truly essential for the overall health of the body including the skin, hairs, and nails- Argan Oil. You can take it orally, apply it topically, or get it added to some brilliant cosmetic product. Whichever way, argan oil unlocks its loads ofh...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, will provide an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSy...
Kubernetes is a new and revolutionary open-sourced system for managing containers across multiple hosts in a cluster. Ansible is a simple IT automation tool for just about any requirement for reproducible environments. In his session at @DevOpsSummit at 18th Cloud Expo, Patrick Galbrai...
For better or worse, DevOps has gone mainstream. All doubt was removed when IBM and HP threw up their respective DevOps microsites. Where are we on the hype cycle? It's hard to say for sure but there's a feeling we're heading for the "Peak of Inflated Expectations." What does this mean...
Kubernetes is a new and revolutionary open-sourced system for managing containers across multiple hosts in a cluster. Ansible is a simple IT automation tool for just about any requirement for reproducible environments. In his session at @DevOpsSummit at 18th Cloud Expo, Patrick Galbr...
DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one lo...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers